Germline mutations in tumor suppressor genes, or less frequently oncogenes, have been identified in up to 19 familial cancer syndromes including Li -Fraumeni syndrome, familial paraganglioma, familial adenomatous polyposis coli and breast and ovarian cancers. Multiple genes have been associated with some syndromes as approximately 26 genes have been linked to the development of these familial cancers. With this increased knowledge of the molecular determinants of familial cancer comes an equal expectation for efficient genetic screening programs. We have trialled denaturing highperformance liquid chromatography ( dHPLC ) as a tool for rapid germline mutation scanning of genes implicated in three familial cancer syndromes -Cowden syndrome ( PTEN mutation ), multiple endocrine neoplasia type 2 ( RET mutation ) and von Hippel -Lindau disease ( VHL mutation ). Thirty -two mutations, including 21 in PTEN, 9 in RET plus a polymorphism, and 2 in VHL, were analyzed using the WAVE DNA fragment analysis system with 100% detection efficiency. In the case of the tumor suppressor gene PTEN, mutations were scattered along most of the gene. However, mutations in the RET proto -oncogene associated with multiple endocrine neoplasia type 2 were limited to specific clusters or ''hot spots.'' The use of GC -clamped primers to scan for mutations scattered along PTEN exons was shown to greatly enhance the sensitivity of detection of mutant hetero -and homoduplex peaks at a single denaturation temperature compared to fragments generated using non -GC -clamped primers. Thus, when scanning tumor suppressor genes for germline mutation using dHPLC, the incorporation of appropriate GCclamped primers will likely increase the efficiency of mutation detection. Neoplasia ( 2001 ) 3, 236 -244.
Introduction
The identification of genes associated with familial cancer syndromes has created a commensurate requirement for the efficient scanning of these genes in at -risk family members. Familial cancers account for up to 10% of all malignancies. Germline mutation in a tumor suppressor or, less frequently an oncogene, has been identified as the primary genetic event linked to an increased risk of developing specific malignancies in approximately 19 familial syndromes. In some cases, such as hereditary nonpolyposis colon cancer ( HNPCC ), mutation of more than one gene has been associated with the clinical phenotype, implicating approximately 26 genes as ''caretakers'' or ''gatekeepers'' for the development of human cancer in the familial setting ( Ref. [ 1 ] , reviewed in Ref. [ 2 ] ). It has been estimated that as many as 50 different genes may eventually be identified where carriers of heterozygous mutations will have an increased risk of developing cancer [ 3 ] .
With this increased clarification of the molecular basis of many inherited cancers comes the opportunity to offer efficient genetic screening programs coupled with the collection of family histories that will allow for noninvasive assessment of asymptomatic at -risk individuals, increase the diagnostic power of clinicians and permit directed cancer surveillance. We, and others, have previously reported genetic screening of patients and their relatives with three distinct inherited cancer syndromes -multiple endocrine neoplasia type 2 ( MEN 2 ) [ OMIM#171400 ] and germline mutation of the proto -oncogene RET; von Hippel -Lindau disease ( VHL ) [ OMIM#193300 ] and germline mutation of the tumor suppressor VHL; and Cowden syndrome ( CS ) [ OMIM#158350 ] with germline mutation of the tumor suppressor PTEN [ 4 -7 ] . In addition, Bannayan -RileyRuvalcaba syndrome ( BRR ) [ OMIM#153480 ] , has been shown to be part of the clinical spectrum of CS, and approximately half carry a germline mutation of PTEN [8] .
The most common clinical features of MEN 2, VHL, CS, and BRR are summarized in Table 1 .
In the case of the tumor suppressor genes PTEN and VHL, mutations are scattered along the majority of the gene. However, in contrast, mutations in the RET proto -oncogene associated with MEN 2 are targeted to specific codons. The mutation type, location and the frequency with which these genes are mutated in the germline in association with a familial cancer syndrome are summarized in Table 2 . Comprehensive mutation summaries for these and additional genes can be located at the Human Gene Mutation Database ( HGMD ) website, http: / / www.uwcm.ac.uk / uwcm / mg / hgmd0.html.
In this study, we report the efficient use of denaturing high -performance liquid chromatography ( dHPLC ) for mutation scanning in three familial cancer syndromes, and their variants, where mutations are either clustered in ''hot spots'' or scattered along the entire gene.
Materials and Methods

Patients and Samples
Blood samples from the probands of 21 families with CS and / or BRR, 9 families with MEN 2, and 2 families with VHL were collected for analysis. Constitutional DNA was extracted from blood leucocytes using standard techniques [ 18 ] . Germline mutation of PTEN had previously been reported in 20 of the CS or BRR families identified using denaturing gradient gel electrophoresis ( DGGE ), temporal temperature gel electrophoresis ( TTGE ), or sequencing [ 4, 5 ] ( Table 3 ). All RET mutants had previously been reported by us or others [ 6, 13 ] . The two VHL mutants described in this study had previously been reported by others [ 14, 19 ] ( http: / / www.uwcm.ac.uk / uwcm / mg / hgmd0.html ) ( Table 3 ). In addition, blood was collected from four at -risk members of one of the VHL families for analysis.
Polymerase Chain Reaction and Sequencing
Primer sequences and PCR conditions for the amplification of GC -clamped PTEN fragments have been previously reported [ 20 -23 ] . In addition, four PTEN exons, or amplicons, and flanking intronic sequences were amplified using non -GC -clamped primers, identical to the GCclamped primers previously published, however, missing the GC -clamp as follows: amplicon 5I, 5IFnogc [ 20, 21, 23 ] . PCR conditions and primer sequences for amplification of the RET proto -oncogene have, in general, been previously reported. Exon 10 was amplified using 7F and 7R with the addition of 10% dimethyl sulfoxide ( Sigma Chemical Co, Castle Hill, NSW, Australia ) [ 24 ] ; exon 11 was amplified using 8AR [ 24 ] and 11F, 5 0 -AGC CAT GAG GCA GAG CAT AC -3 0 ; exon 15 was amplified using 17B and 17G [ 25 ] , and exon 16 was amplified using fRET16 and rRET16 [ 26 ] .
Primer sequences for the amplification of VHL exon 3 were modified from those previously published [ 27 ] , specifically 40Fmod, All PCR products were generated using a MJ Peltier Thermal Cycler PTC -100 ( MJ Research, Watertown, MA ). PCR products destined for dHPLC analysis underwent additional cycling after amplification, consisting of a denaturation step of 948C for 5 minutes followed by ramping to 258C over 45 minutes to allow the formation of homo -and heteroduplexes in samples heterozygous for a mutant allele. No additional purification procedures were required. Product sizes ranged from 178 to 396 nucleotides. PCR products destined for sequence analysis were purified using the Wizard PCR Preps DNA Purification System ( Promega, Madison, WI ). Direct sequencing of these products was performed using the ABI Prism BigDye Terminator cycle sequencing ready reaction kit ( Applied Biosystems, PerkinElmer ). Purified cycle sequencing products were electrophoresed on 4.8% PAGE Plus gels ( Amresco, Cleveland, OH ) and analyzed on a 377XL automated DNA sequencer ( Applied Biosystems, Perkin -Elmer ). Exons 7 and 8 are believed to encode the potential tyrosine and serine phosphorylation sites ( reviewed in Ref. [ 17 ] ).
Denaturing HPLC DHPLC was undertaken on a WAVE DNA fragment analysis system ( Transgenomic, Omaha, NE ). Two to five microliters of heteroduplexed PCR fragments was injected onto the DNASep cartridge. Products were eluted at a constant flow rate of 0.9 ml / min with a linear acetonitrile gradient determined by WAVEMaker software ( Transgenomic, Omaha, NE ) based on the size and GC content of the amplicon. The gradient was achieved by combining 0.1 M triethylammonium acetate ( TEAA ) buffer ( pH 7 ) ( Transgenomic ) and Buffer B ( 0.1 M TEAA with 25% acetonitrile ) ( Transgenomic ). Eluted DNA fragments were detected by the system's UV detector and analyzed as chromatograms. The processing time for each sample was comprised of a 2.2 -minute lag for the detector, 0.5 minutes loading with a 5% decrease in Buffer B, a 4.5 -minute linear gradient with a slope of 2% increase in Buffer B per minute, a 0.5 -minute cleaning stage using 75% acetonitrile, and a 0.9 -minute equilibration before the next injection. Homo -and heteroduplex peaks were detected between the initial injection peak, produced by residual nucleotides and primers in the reaction, and the wash peak, produced by the acetonitrile flush at the end of each analysis.
Melt profiles were constructed using the WAVEMaker software ( Transgenomic ) using PCR fragments in the size range of 178 to 344 base pairs ( non -GC -clamped fragments ) and 218 to 396 base pairs ( GC -clamped fragments ). A range of partial denaturation temperatures was predicted by this software ( Table 3 ) . PCR products were initially analyzed under nondenaturing conditions, 508C, to assess the quality of the peak representing both hetero -and homoduplex DNA fragments in a mutant sample. All temperatures within the predicted range for partial denaturation were then assessed for their ability to resolve homo -and heteroduplexes. A single temperature was chosen where all mutants could be resolved. Given that heteroduplexes are less stable, they denatured earlier than the homoduplexes and so were seen first in the elution profile.
Results
Thirty -two known mutations and one polymorphism previously determined by sequence analysis and / or restriction endonuclease digestion, 21 in PTEN, 9 in RET plus a polymorphism, and 2 in VHL, were detected by dHPLC at temperatures within the range predicted by the WAVEMaker software ( Transgenomic ) ( Table 3 ). The mutation R47G in exon 2 of PTEN identified in a family with CS has not been previously reported. The clinical symptoms of CS in this family included gastrointestinal polyps, multiple fibroadenomas of the breast, Hashimoto's thyroiditis and goiter, lipomas, and papules of the oral mucosa.
The value of GC -clamped primers for use in dHPLC mutation detection was directly assessed in four PTEN exons or amplicons -5I, 5II, 7, and 8. Two to five separate mutations, well scattered over the exon, were analyzed in each case for detection of all mutants at a single temperature. The nonsense PTEN point mutation R233X in exon 7 was poorly discernible when analysis was undertaken using non -GC -clamped primers at all temperatures predicted by the WAVEMaker software ( Transgenomic ). In addition, temperatures up to 708C, at which the peak had largely collapsed, were unable to resolve this mutant. However, resolution of the heteroduplexed fragments was clearly observed using a PCR amplicon generated by identical primers with the addition of a GC -clamp ( Figure 1A ). Of interest, the elution profile of the wild -type DNA of GCclamped PTEN exon 7 shows an apparent peak preceding the homoduplex peak ( Figure 1A ). This peak was not observed in non -GC -clamped PTEN exon 7. The same wild -type DNA was used for both experiments and shown by sequence analysis to be free of sequence variants. It is most likely that this apparent peak represents an artifact introduced by the GC clamp. Clearly, however, the GC -clamped PTEN exon 7 wild type shows a distinctly different elution profile to both the R233X and IVS6 -1G > C exon 7 mutants.
Artifact peaks before the appearance of homo -and heteroduplex peaks in the elution profile likely due to the method of sample preparation were also detected ( Figure  2A ). These artifact peaks could be decreased relative to true homo -and heteroduplex peaks by dilution of the template DNA before PCR amplification, excluding the possibility that they represented true peaks. The presence of artifacts highlights the importance of including wild -type DNA controls in each experiment.
An intronic polymorphism present in amplicon 8, IVS8 + 32 T / G [ 28 ] was not detectable at the temperature used for mutation analysis of exon 8 ( Table 3 , data not shown ). This Figure 1 . dHPLC analysis of PTEN exons or amplicons. ( A ) PTEN exon 7 analyzed as both a GC -clamped and a non -GC -clamped fragment. The mutation R233X is scarcely detectable in the elution profile of the nonclamped exon 7 fragment compared to the GC -clamped fragment. Increased resolution of the elution profile is also observed for the splice site mutation IVS6 -1G > C. ( B ) PTEN amplicon 5I analyzed as both a GC -clamped and a non -GC -clamped fragment. Two missense point mutations, C105Y and Q110X, a small deletion -insertion, c.302 -304delTCAinsCC, and a deletion, c347 -351delACAAT, were able to be discriminated from the wild -type sequence using non -GC -clamped primers, however, resolution was significantly improved using primers with a GC clamp.
was likely due to this variant's location in an almost fully denatured region of the melt profile. In general, the use of GC -clamped primers for PCR amplification of PTEN greatly improved the resolution of hetero -and homoduplex peaks, dramatically improving the efficiency of user interpretation ( Figure 1, A and B ) .
Given the clustered nature of RET mutations, dHPLC was optimized using non -GC -clamped primers ( Table 3 ). All nine missense mutations were able to be differentiated from the wild -type DNA homoduplexes in the four exons analyzed ( Figure 2, A-E) . C634G and C634S in RET exon 11 ( Figure 2B ) showed more subtle changes in their elution profiles, yet were still discernible from wild -type DNA. A silent polymorphism in RET exon 15 resulting from a C!G substitution, S904S, was detected at 638C ( Figure  2D ) [ 29 ] . This polymorphism was also present in the individual shown to carry the A883F mutation ( 041, Table  3 ). Of interest, this polymorphism was not detected at Figure 2 . dHPLC analysis of RET and VHL exons. ( A -E ) Nine clustered mutations and a polymorphism in RET exon 10, 11, 15, and 16 were able to be resolved. C618R and C620R ( exon 10 ), C634R and C634Y ( exon 11 ), A883F, S891A and S904S ( exon 15 ), and M918T ( exon 16 ) showed elution profiles distinctly resolvable from the wild -type amplicon for each exon. C634G and C634S ( exon 11 ) showed elution profiles with more subtle variation from wild -type exon 11. ( F ) The elution profiles of two missense point mutations in VHL exon 3, T157I and R161X, were clearly distinct from wild -type sequence.
508C in the wild -type DNA, subsequently shown by sequence analysis to be positive for S904S. However, DNA from individual 041 containing both the A883F mutation and the S904S polymorphism did form heteroduplexes at this temperature ( Figure 2C ). The mutant S891A was unable to be resolved at 508C. Therefore, even though the polymorphism was unable to be detected at 508C, thus excluding it as a normal variant in the elution profile, the inability to detect all RET exon 15 mutants at this temperature excluded the possibility of conducting mutation scanning at this temperature.
Only two VHL mutants, mapping within nine nucleotides of each other in VHL exon 3, were available for analysis. Again, given the close proximity of these mutants, dHPLC was optimized using non -GC -clamped primers ( Table 3, Figure  2F ). Further, dHPLC was used to screen four additional asymptomatic at -risk members of one of the VHL families, V02. The elution profile for all asymptomatic individuals, aged 5 to 11 years, matched that of the proband and was clearly different to wild -type DNA analyzed as a control in the same experiment. Sequence analysis confirmed that these individuals were positive for R161X.
Discussion
The underlying primary genetic mutations associated with an increasing number of familial cancer syndromes are rapidly being identified. Greater understanding of the molecular basis of many of these inherited syndromes allows for the development of efficient genetic screening programs to identify family members at risk of developing cancer, thus allowing directed cancer surveillance for mutation carriers. We have employed a dHPLC system, WAVE DNA fragment analysis system ( Transgenomic ), for rapid germline mutation screening in two tumor suppressor genes, PTEN and VHL, and one oncogene, RET, mutations of which are associated with CS, VHL disease, and MEN 2, respectively. The efficiency of mutation detection in PTEN was increased by the use of GC -clamped primers resulting in 100% ( N = 32 ) of mutations plus a polymorphism being identified by dHPLC. These mutations had previously been identified by the more labor -intensive techniques of DGGE and TTGE ( PTEN ) [ 4, 5 ] ; sequencing and / or restriction endonuclease digestion ( PTEN, VHL, and RET ) [ 4, 5, 16, 30 ] . In addition, dHPLC was used to provide a rapid screen of four asymptomatic individuals, age range 5 to 11 years, of unknown genetic carrier status in the VHL family V02. All individuals were shown to be positive for the R161X mutation and appropriate, directed cancer surveillance has now been recommended for these patients.
Although mutation hot spots are seen in many of the tumor suppressor genes linked to familial cancer syndromes, in general, germline mutations are scattered largely along the entirety of the gene [ 31 -33 ] . Germline mutation of PTEN in CS and BRR also follows this pattern, making efficient dHPLC mutation detection at a single temperature for each specific amplicon impossible due to variation of the fragment's melt profile. For reliable mutation detection using non -GC -clamped primers, analyses will need to be performed at multiple temperatures to ensure detection of all mutants as has been previously reported [ 34 ] . In general, the use of GC -clamped primers allows the generation of a more uniform melt profile, thus leading to improved resolution of hetero -and homoduplex peaks in the elution profile. Analyses performed at a single temperature are then more likely to generate elution profiles clearly defining mutant samples, regardless of the position of the mutation in the amplicon. In a direct comparison of GC -clamped and non -GC -clamped PTEN amplicons, mutants that were poorly discernible as nonclamped fragments were able to be clearly resolved when generated as part of a GCclamped amplicon ( Figure 1 ). Perhaps the most dramatic example of this increased resolution was seen in the case of the germline mutant R233X ( Figure 1A ). This mutant was reported in a study of somatic PTEN mutations in small cell lung carcinoma using dHPLC where it was also shown to be poorly resolved [ 35 ] . In general, the use of GC -clamped primers for dHPLC greatly improved the resolution of homoand heteroduplex peaks, clearly improving the efficiency of this methodology.
Similar to other more traditional mutation scanning methods such as DGGE and SSCP, the presence of polymorphisms can present a complicating factor when using dHPLC to screen for germline mutations. Although a known intronic polymorphism in PTEN, IVS8 + 32 T / G, was not detected at the temperature chosen to screen for mutants, the RET polymorphism S904S was clearly evident in the elution profile of the fragment containing RET exon 15 ( Figure 2D ). The inability to detect the PTEN intronic polymorphism was likely due to its location in an almost fully denatured region of the melt profile. However, the presence of the RET exon 15 polymorphism likely influenced the elution profile of the A883F mutant, as the single patient with this mutation, a case of de novo MEN 2B, also had this polymorphism ( Figure 2D ). An earlier study using dHPLC to screen for RET mutations only analyzed exon 10 mutants [ 34 ] . To date, polymorphisms have not been reported in this exon. The presence of polymorphisms must be considered when using dHPLC to screen members of hereditary cancer families at risk of inheriting the disease allele.
A second genetic aberration that complicates screening with dHPLC is gross germline deletion. To date, gross germline deletion of PTEN has not been reported to be associated with CS; however, three cases of gross germline deletion of the 10q23 region encompassing PTEN have been reported [ 5, 36, 37 ] . Gross germline deletion of VHL and its flanking intervals is a more common phenomenon and has been reported in up to 25% of VHL families [ 7 ] . It is important to recognize that dHPLC would be an unsuitable mutation detection method in cases of germline whole gene deletion as the presence of only one wild -type allele would preclude the formation of heteroduplexes and thus a definitive elution profile. In the case of VHL screening, dHPLC could be used as an initial screen for the detection of germline intragenic mutations. If no mutations were detected in this first screen, DNA from probands of these families could undergo alternative screening to detect putative deletions of the entire VHL gene using methods such as quantitative Southern blotting or fluorescence in situ hybridization as have been previously recommended [ 16 ] .
The arising complication from the presence of a single allele when screening with dHPLC is also relevant when studying somatic mutations of tumor suppressor genes in tissues where the wild -type allele is lost. A study of somatic PTEN mutation by dHPLC in 63 malignant gliomas showed that low -level amounts of normal contaminant DNA, 10% to 20%, enabled the formation of detectable heteroduplexes in 13 samples where the wild -type PTEN allele had been lost and a mutation was present in the retained allele [ 34 ] . However, perhaps more reliably for the analysis of DNA from tumor tissue, wild -type PCR product could be admixed with the tumor or cell line PCR product known to show allelic loss to mimic the presence of a wild -type allele, then denatured, reannealed and screened for heteroduplex peaks by dHPLC [ 35 ] .
Given the examples of VHL and PTEN where whole gene deletion has been identified in the germline, a wild -type allele is also retained. Therefore the method of admixing wild -type DNA with a test sample would not be suitable for germline DNA analyses.
A number of studies have been performed to directly compare dHPLC with the more established mutation detection methodologies of single -strand conformation polymorphism and heteroduplex analysis. In studies of known mutations of BRCA1, the cystic fibrosis transmembrane conductance regulator gene, CFTR, and the tuberous sclerosis complex genes, TSC1 and TSC2, dHPLC detected 96% to 100% of mutations, SSCP 85% to 94%, and heteroduplex analysis only 82% [ 31, 38 ] . In a further study of 150 unrelated cases with tuberous sclerosis, dHPLC was shown to detect mutations in 68% of cases, SSCP in 61% and heteroduplex analysis in only 58% [ 39 ] . In addition, a blinded comparison of DGGE and dHPLC used to screen BRCA1 in 41 probands from hereditary breast and ovarian cancer families showed that dHPLC was able to detect a mutant that was not identified by DGGE [ 40 ] . To date, no false -positives have been identified using dHPLC [ 31, 33, 34, 41 ] .
In summary, we have described a novel application for GC -clamped amplicons to increase the sensitivity of dHPLC allowing accurate screening at a single temperature of the tumor suppressor gene PTEN associated with CS and the related syndrome BRR. This method has applicability to other tumor suppressor genes associated with familial cancer syndromes including BRCA1, BRCA2, and MEN1 where mutations are scattered largely along the entirety of the gene. When planning the implementation of a germline genetic screening program for inherited cancer syndromes incorporating dHPLC, it is essential to take into consideration the spectrum of mutations, including gross germline deletion and polymorphisms, that have been previously described to permit accurate interpretation of dHPLC elution profiles.
